C. Schwimmer

发表

The mitochondrial ADP/ATP carrier: structural, physiological and pathological aspects.

A. Le Saux, V. Trézéguet, G. Lauquin, 1998, Biochimie.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

A. Antinori, F. Raffi, G. Chêne, 2014, The Lancet.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Four Mutations in Transmembrane Domains of the Mitochondrial ADP/ATP Carrier Increase Resistance to Bongkrekic Acid

V. Trézéguet, G. Lauquin, G. Brandolin, 2003, Journal of bioenergetics and biomembranes.

Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study

F. Raffi, D. Carr, G. di Perri, 2022, The Pharmacogenomics Journal.

Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)

J. Durrieu, J. Montastruc, J. Chastang, 2022, Clinical Microbiology and Infection.

Physiology and Pathophysiology of the Mitochondrial ADP/ATP Carrier

V. Trézéguet, G. Lauquin, G. Brandolin, 1999 .

Purification of histidine-tagged mitochondrial ADP/ATP carrier: influence of the conformational states of the C-terminal region.

A. Le Saux, V. Trézéguet, G. Lauquin, 2000, Protein expression and purification.

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2016, International journal of epidemiology.

Conformational changes of the beef heart and yeast mitochondrial ADP/ATP carrier

V. Trézéguet, G. Lauquin, G. Brandolin, 1995 .

Increasing Mitochondrial Substrate-level Phosphorylation Can Rescue Respiratory Growth of an ATP Synthase-deficient Yeast*

Piotr P Slonimski, M. Rigoulet, P. Slonimski, 2005, Journal of Biological Chemistry.

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project

D. Pillay, C. Sabin, T. Klimkait, 2016, BMC Infectious Diseases.

Yeast models of human mitochondrial diseases: from molecular mechanisms to drug screening

S. Duvezin-Caubet, J. di Rago, Malgorzata Rak, 2006, Biotechnology journal.

Inactivation of Saccharomyces cerevisiae OGG1 DNA repair gene leads to an increased frequency of mitochondrial mutants.

B. Sigala, K. Singh, C. Schwimmer, 2001, Nucleic acids research.

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

S. Lees, D. Watson-Jones, M. Belson, 2020, Trials.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Antagonistic Interactions between Yeast [PSI+] and [URE3] Prions and Curing of [URE3] by Hsp70 Protein Chaperone Ssa1p but Not by Ssa2p

D. Masison, Christine Schwimmer, Daniel C. Masison, 2002, Molecular and Cellular Biology.

A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations

C. Morrison, P. Vanhems, A. Kamali, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD)

F. Collette, J. Molinuevo, G. Rauchs, 2018, Alzheimer's & dementia.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

H. Jessen, A. Blaxhult, V. Calvez, 2016, The Journal of antimicrobial chemotherapy.

Fluorometric titration of the mitochondrial ADP/ATP carrier protein in muscle homogenate with atractyloside derivatives.

A. Le Saux, V. Trézéguet, G. Lauquin, 1996, Analytical biochemistry.

Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial

B. Rodés, F. Raffi, J. Arribas, 2019, HIV medicine.

Measuring Psychological Mechanisms in Meditation Practice: Using a Phenomenologically Grounded Classification System to Develop Theory-Based Composite Scores

F. Collette, G. Rauchs, A. Lutz, 2021, Mindfulness.

Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143

F. Wit, F. Raffi, A. Pozniak, 2014, Journal of the International AIDS Society.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

A. Antinori, F. Raffi, W. Stöhr, 2018, Journal of acquired immune deficiency syndromes.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

A. Antinori, F. Raffi, W. Stöhr, 2018, Journal of acquired immune deficiency syndromes.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

J. Sterne, A. Sabin, A. Mocroft, 2018, HIV medicine.

Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1

B. Rodés, M. Gisslén, F. Raffi, 2018, The Journal of infectious diseases.

Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

B. Gazzard, A. Mocroft, O. Kirk, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.